- Trials with a EudraCT protocol (22)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
22 result(s) found for: Gliosarcoma.
Displaying page 1 of 2.
| EudraCT Number: 2009-011898-33 | Sponsor Protocol Number: HIT-HGG-CilMetro | Start Date*: 2011-11-28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Treatment of relapsed or refractory high grade gliomas and diffuse intrinsic pontine gliomas in paediatric patients ≥ 3 years and < 18 years of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-000128-42 | Sponsor Protocol Number: HIT-HGG-2007 | Start Date*: 2009-03-19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-University Halle-Wittenberg | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adole... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: 1st line therapy of newly diagnosed, previously untreated high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents ≥ 3 years and < 18 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2006-001278-26 | Sponsor Protocol Number: VEG102857 | Start Date*: 2006-10-31 |
| Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
| Full Title: Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma | ||
| Medical condition: Relaped Malignant Glioma = patients with anaplastic astrocytoma, anaplastic oligodendroglioma, mixed anaplastic oligoastrocytoma, glioblastoma multiforme or gliosarcoma at recurrence | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-004187-56 | Sponsor Protocol Number: HIT-HGG-2013 | Start Date*: 2017-04-24 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Georg-August-Universität Göttingen, Stiftung Öffentlichen Rechts, Universitätsmedizin Göttingen | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: First-line therapy of newly diagnosed, previously untreated high grade glioma, diffuse pontine glioma, and gliomatosis cerebri in children and adolescents <18 years. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) NL (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2006-005077-21 | Sponsor Protocol Number: DCOG 0423 | Start Date*: 2007-02-12 |
| Sponsor Name:Dutch Childhood Oncology Group (DCOG) | ||
| Full Title: A Phase II study of concurrent radiation and Temozolomide followed by Temozolomide and Lomustine (CCNU) in the treatment of Children with High Grade Glioma | ||
| Medical condition: High grade glioma: anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2017-003171-64 | Sponsor Protocol Number: M16-534 | Start Date*: 2018-10-30 | |||||||||||
| Sponsor Name:AbbVie Deutschland GmbH & Co.KG | |||||||||||||
| Full Title: Phase 3b Study for Management of Ocular Side Effects in Subjects with EGFR-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414) | |||||||||||||
| Medical condition: EGFR-Amplified Newly diagnosed glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) NL (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-000095-15 | Sponsor Protocol Number: OCTO_090 | Start Date*: 2018-11-02 | |||||||||||
| Sponsor Name:University of Oxford | |||||||||||||
| Full Title: A Phase II, Open Label, Randomised Study of Ipilimumab With Temozolomide Versus Temozolomide Alone after Surgery and Chemoradiotherapy in Patients with Recently Diagnosed Glioblastoma (IPI-GLIO) | |||||||||||||
| Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002250-24 | Sponsor Protocol Number: GCAR-7213 | Start Date*: 2021-12-07 | |||||||||||
| Sponsor Name:Global Coalition for Adaptive Research | |||||||||||||
| Full Title: GCAR-7213: GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Di... | |||||||||||||
| Medical condition: Oncology - Glioblastoma (GBM) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) FR (Trial now transitioned) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-001166-26 | Sponsor Protocol Number: M13-813 | Start Date*: 2015-12-28 | |||||||||||
| Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
| Full Title: A Randomized, Placebo Controlled Phase 3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor R... | |||||||||||||
| Medical condition: Newly diagnosed glioblastoma (GBM) or gliosarcoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) NL (Completed) IE (Completed) DE (Completed) BE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) PT (Completed) ES (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-004457-15 | Sponsor Protocol Number: EMD 121974-012 | Start Date*: 2010-08-13 | |||||||||||
| Sponsor Name:Merck KGaA | |||||||||||||
| Full Title: Cilengitide in subjects with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter - a multicenter, open-label Phase II study, investigating two cilengitide regimens in combin... | |||||||||||||
| Medical condition: Newly diagnosed glioblastoma multiforme with unmethylated MGMT gene promoter status | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) IT (Prematurely Ended) FR (Completed) HU (Completed) AT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-002272-14 | Sponsor Protocol Number: CDX110-07 | Start Date*: 2013-01-11 | |||||||||||
| Sponsor Name:CELLDEX THERAPEUTICS | |||||||||||||
| Full Title: An International, Randomized, Double-Blind, Controlled Phase II Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glio... | |||||||||||||
| Medical condition: Newly diagnosed, surgically resected, EGFRvIII-positive Glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-004558-24 | Sponsor Protocol Number: CC-115-ST-001 | Start Date*: 2012-06-29 | |||||||||||
| Sponsor Name:Celgene Corporation | |||||||||||||
| Full Title: A PHASE 1A/1B, MULTICENTER, OPEN LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF THE DUAL DNA-PK AND TOR KINASE INHIBITOR, CC-115, ADMINIS... | |||||||||||||
| Medical condition: Subjects with advanced solid tumors, non-hodgkin lymphoma (NHL) and multiple myeloma (MM). | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-011252-22 | Sponsor Protocol Number: CeTeG | Start Date*: 2010-07-09 | |||||||||||
| Sponsor Name:Medical Faculty, University of Bonn | |||||||||||||
| Full Title: Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients (CeTeG) | |||||||||||||
| Medical condition: Newly diagnosed patients with glioblastoma harbouring a methylated MGMT promoter | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-004058-17 | Sponsor Protocol Number: CV-006 | Start Date*: 2016-02-22 | |||||||||||
| Sponsor Name:CytoVac A/S | |||||||||||||
| Full Title: An open-label, randomised, Phase II study to investigate the efficacy and safety of ALECSAT treatment as an add-on therapy to radiotherapy and temozolomide in patients with newly diagnosed gliobl... | |||||||||||||
| Medical condition: Glioblastoma multiforme | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000708-39 | Sponsor Protocol Number: NEU-201901 | Start Date*: 2021-07-16 | |||||||||||
| Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn | |||||||||||||
| Full Title: Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy | |||||||||||||
| Medical condition: Adult patients with IDHwt, MGMT promotor methylated glioblastoma at first relapse | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-000192-37 | Sponsor Protocol Number: 2019_0007 | Start Date*: 2021-10-04 | ||||||||||||||||
| Sponsor Name:Hôpital Foch | ||||||||||||||||||
| Full Title: Oxidative Phosphorylation Targeting In Malignant glioma Using Metformin plus radiotherapy temozolomide | ||||||||||||||||||
| Medical condition: Patients with a diagnosis of Glioblastoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2009-012324-83 | Sponsor Protocol Number: UZB-BN-09-001 | Start Date*: 2009-07-04 | |||||||||||
| Sponsor Name:Prof Bart Neyns | |||||||||||||
| Full Title: CeCil: A randomized, non-comparative phase II clinical trial of the effect of radiation therapy plus Temozolomide combined with Cilengitide or Cetuximab on the 1-year overall survival of patients w... | |||||||||||||
| Medical condition: Subjects with newly diagnosed glioblastoma, who have met all eligibility criteria for the CENTRIC study (EMD 121974-011 study, EudraCT 2007-004344-78) with the exception of NOT having a tumor with ... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-006068-32 | Sponsor Protocol Number: CDX110-04 | Start Date*: 2012-07-04 | |||||||||||
| Sponsor Name:Celldex Therapeutics, Inc | |||||||||||||
| Full Title: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma ... | |||||||||||||
| Medical condition: Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Completed) IT (Prematurely Ended) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-000200-23 | Sponsor Protocol Number: 2017-BN-001 | Start Date*: 2017-05-04 | ||||||||||||||||
| Sponsor Name:UZ Brussel | ||||||||||||||||||
| Full Title: Phase II clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastoma | ||||||||||||||||||
| Medical condition: recurrent glioblastoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2022-000627-20 | Sponsor Protocol Number: F8394-201 | Start Date*: 2023-02-07 | ||||||||||||||||
| Sponsor Name:Fore Biotherapeutics | ||||||||||||||||||
| Full Title: A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations | ||||||||||||||||||
| Medical condition: Tumors harboring BRAF alterations | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) DE (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
